Christian Lodberg Hvas

Christian Lodberg Hvas

Auto-generated profile, based on publicly available information

Christian Lodberg Hvas

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
SBStephan C. Bischoff
Stephan C. Bischoff
PBPalle Bager
Palle Bager
JEJohanna Escher
Johanna Escher
AFAlastair Forbes
Alastair Forbes
XHXavier Hébuterne
Xavier Hébuterne
Arved WeimannArved Weimann
Arved Weimann

1 April 2019 in Gastroenterology
Verified
Journal Article
Open access
CHChristian Lodberg Hvas
Christian Lodberg Hvas
SBSimon Mark Dahl Baunwall
Simon Mark Dahl Baunwall
SJSøren Peter Jørgensen
Søren Peter Jørgensen
MSMerete Storgaard
Merete Storgaard
LLLars Lemming
Lars Lemming
JDJens Frederik Dahlerup
Jens Frederik Dahlerup
Fecal microbiota transplantation (FMT) is recommended for treatment of recurrent Clostridium difficile infection (rCDI). We performed a single-center randomized trial to compare the effects of FMT with those of fidaxomicin and vancomycin. We studied consecutive adults with rCDI seen at a gastroenterology clinic in Denmark from April 5, 2016 through June 10, 2018. Patients were randomly assigned to a group that received FMT, applied by colonoscopy or nasojejunal tube, after 4-10 days of vancomycin (125 mg 4 times daily; FMTv; n = 24), 10 days of fidaxomicin (200 mg twice daily; n = 24), or 10 days of vancomycin (125 mg 4 times daily; n = 16). Patients who had rCDI after this course of treatment and patients who could not be randomly assigned to groups were offered rescue FMTv. The primary outcome was combined clinical resolution and a negative result from a polymerase chain reaction test for Clostridium difficile (CD) toxin 8 weeks after the allocated treatment. Secondary end points included clinical resolution at week 8. All 64 patients received their assigned treatment. The combination of clinical resolution and negative results from the test for CD were observed in 17 patients given FMTv (71%), 8 patients given fidaxomicin (33%), and 3 patients given vancomycin (19%; P = .009 for FMTv vs fidaxomicin; P = .001 for FMTv vs vancomycin; P = .31 for fidaxomicin vs vancomycin). Clinical resolution was observed in 22 patients given FMTv (92%), 10 patients given fidaxomicin (42%), and 3 patients given vancomycin (19%; P = .0002; P < .0001; P = .13). Results did not differ significantly between patients who received FMTv as their initial therapy and patients who received rescue FMTv. There was 1 serious adverse event that might have been related to FMTv. In a randomized trial of patients with rCDI, we found the FMTv combination superior to fidaxomicin or vancomycin based on end points of clinical and microbiological resolution or clinical resolution alone. ClinicalTrials.gov, number NCT02743234; EudraCT, j.no 2015-003004-24.

6 July 2010 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SJS. P. Jørgensen
S. P. Jørgensen
JAJørgen Agnholt
Jørgen Agnholt
HGH. Glerup
H. Glerup
SLS. Lyhne
S. Lyhne
GVG. E. Villadsen
G. E. Villadsen
JDJ. F. Dahlerup
J. F. Dahlerup

1 July 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MJMette Julsgaard
Mette Julsgaard
LCLisbet A. Christensen
Lisbet A. Christensen
PGPeter R. Gibson
Peter R. Gibson
RGRichard Gearry
Richard Gearry
JFJan Fallingborg
Jan Fallingborg
SBSally J. Bell
Sally J. Bell

1 November 2013 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
SJSøren Peter Jørgensen
Søren Peter Jørgensen
CHChristian Lodberg Hvas
Christian Lodberg Hvas
JAJørgen Agnholt
Jørgen Agnholt
LCLisbet Ambrosius Christensen
Lisbet Ambrosius Christensen
LHLene Heickendorff
Lene Heickendorff
JDJens Frederik Dahlerup
Jens Frederik Dahlerup
Crohn's disease prevalence increases with increasing latitude. Because most vitamin D comes from sunlight exposure and murine models of intestinal inflammation have demonstrated beneficial effects of 1,25-(OH)2 vitamin D treatment, we hypothesised that Crohn's disease activity is associated with low vitamin D levels. In a cross-sectional study of 182 CD patients and 62 healthy controls, we measured serum 25-OH vitamin D. Stratified analysis was used to compare 25-OH vitamin D levels with Crohn's disease activity index, C-reactive protein, smoking status, intake of oral vitamin D supplements and seasonal variation in CD patients and healthy controls. Serum 25-OH vitamin D was inversely associated with disease activity: Median 25-OH vitamin D levels of Crohn's disease in remission, mildly, and moderately active diseases evaluated by Crohn's disease activity index were 64, 49, and 21 nmol/l (p<0.01) and by CRP 68, 76, and 35 nmol/l (p<0.05), respectively. Patients who took oral vitamin D supplementation had lower Crohn's disease activity index (p<0.05) and C-reactive protein (p=0.07) than non-users. Crohn's disease patients who smoked had lower vitamin D levels (51 nmol/l) than patients who did not smoke (76 nmol/l), p<0.01. Overall, Crohn's disease patients did not differ from healthy controls regarding 25-OH vitamin D levels. Active Crohn's disease was associated with low serum 25-OH vitamin D. Patients who smoked had lower 25-OH vitamin D levels than patients who did not smoke, independently of disease activity.

1 July 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
MJMette Julsgaard
Mette Julsgaard
MNMette Nørgaard
Mette Nørgaard
CHChristian Lodberg Hvas
Christian Lodberg Hvas
DBDaniel Buck
Daniel Buck
LCLisbet Ambrosius Christensen
Lisbet Ambrosius Christensen
Background. Adherence to medical treatment among women with ulcerative colitis (UC) prior to and during pregnancy has never been investigated. The aim w